Chordate Medical Holding AB (OSTO:CMH) Total Current Assets : kr12.76 Mil (As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Chordate Medical Holding AB Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Chordate Medical Holding AB's total current assets for the quarter that ended in Dec. 2023 was kr12.76 Mil.

Chordate Medical Holding AB Total Current Assets Historical Data

The historical data trend for Chordate Medical Holding AB's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chordate Medical Holding AB Total Current Assets Chart

Chordate Medical Holding AB Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Current Assets

Get a 7-Day Free Trial

6.61

18.42

31.51

8.15

12.76

Chordate Medical Holding AB Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Current Assets	Get a 7-Day Free Trial															8.15	32.61	25.58	19.92	12.76

Chordate Medical Holding AB Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Chordate Medical Holding AB's Total Current Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	8.455	+	1.671	+	1.771	+	0.861
	=	12.76

Chordate Medical Holding AB's Total Current Assets for the quarter that ended in Dec. 2023 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	8.455	+	1.671	+	1.771	+	0.861
	=	12.76

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Chordate Medical Holding AB (OSTO:CMH) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Chordate Medical Holding AB's Liquidation Value for the quarter that ended in Dec. 2023 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	8.455	-	6.869	+	0.75 * 0.211	+	0.5 * 1.771
=	2.63

Chordate Medical Holding AB Total Current Assets Related Terms

Thank you for viewing the detailed overview of Chordate Medical Holding AB's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Chordate Medical Holding AB (OSTO:CMH) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Chordate Medical Holding AB (OSTO:CMH) » Definitions » Total Current Assets

Comparable Companies

Traded in Other Exchanges

K1Z:Germany

Address

c/o Regus, Kistagangen 20B, Kista, SWE, 164 40

Website

https://www.chordate.com

Chordate Medical Holding AB is a medical technology company that has developed and patented and CE-marked a new nerve-modulating treatment technology for chronic nasal congestion and chronic migraine. The company sells its products in Selected European markets, Israel and Saudi Arabia. The company's product range is based on the CE-marked treatment units Chordate System S100 and S120 for rhinitis and S220 for migraine, registered for the indications of preventive treatment of chronic migraine and chronic rhinitis and use on patients who are 18 years old or older. The company sells its product system, including treatments, through distributors to clinics and hospitals in its primary markets.

Chordate Medical Holding AB (OSTO:CMH) Headlines

No Headlines